1
Country: USA | Funding: $1.6B
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
2
Country: USA | Funding: $537.8M
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
3
Country: USA | Funding: $437M
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
4
Country: USA | Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
5
Country: USA | Funding: $301M
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
6
Country: France | Funding: $219.7M
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
7
Country: USA | Funding: $188.8M
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut microbiome.
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut microbiome.
8
Country: USA | Funding: $130.9M
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
9
Country: USA | Funding: $118M
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
10
Country: France | Funding: €101.6M
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
11
Country: Denmark | Funding: $103.4M
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
12
Country: UK | Funding: £62M
Microbiotica's goal is to create the world’s leading company focused on microbiome biology and its use in medicine
Microbiotica's goal is to create the world’s leading company focused on microbiome biology and its use in medicine
13
Country: France | Funding: $74.7M
A unique platform to engineer and intervene on the microbiome. Eligobiotics are a platform technology that can be programmed to leverage the existing microbial populations in the gut, lungs, vagina, skin, etc. This technology can enable a targeted diagnosis, editing, and functionalization of human or animal microbiomes.
A unique platform to engineer and intervene on the microbiome. Eligobiotics are a platform technology that can be programmed to leverage the existing microbial populations in the gut, lungs, vagina, skin, etc. This technology can enable a targeted diagnosis, editing, and functionalization of human or animal microbiomes.
14
Country: USA | Funding: $75.3M
Azitra is a preclinical-stage development company using a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease.
Azitra is a preclinical-stage development company using a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease.
15
Country: South Korea | Funding: $44.6M
Genome & Company is a clinical stage biotechnology company based in Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients.
Genome & Company is a clinical stage biotechnology company based in Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients.
16
Country: USA | Funding: $38,7m
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos.
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos.
17
Country: USA | Funding: $31M
Scioto Biosciences is committed to moving the field of microbiome therapeutics forward. By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.
Scioto Biosciences is committed to moving the field of microbiome therapeutics forward. By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.
18
Country: France | Funding: €22.3M
Exeliom Biosciences develops a bacterial treatment for inflammatory bowel diseases. It's intended to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut.
Exeliom Biosciences develops a bacterial treatment for inflammatory bowel diseases. It's intended to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut.
19
Country: Israel | Funding: $20M
Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases.
Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases.
20
Country: USA | Funding: $16.4M
Astarte Medical delivers technology platforms to address critical needs and improve outcomes for high risk pregnancy and preterm birth.
Astarte Medical delivers technology platforms to address critical needs and improve outcomes for high risk pregnancy and preterm birth.
21
Country: Hong Kong | Funding: $15M
Using next generation sequencing and artificial intelligence, GenieBiome pioneered the use of microbiome to tackle a myriad of diseases, including COVID-19, colorectal cancer, obesity, eczema, and autism.
Using next generation sequencing and artificial intelligence, GenieBiome pioneered the use of microbiome to tackle a myriad of diseases, including COVID-19, colorectal cancer, obesity, eczema, and autism.
22
Country: Singapore | Funding: $10.5M
Asian Microbiome Library microbiome company and a stool bank serving as a hub for gut microbiome therapy.
Asian Microbiome Library microbiome company and a stool bank serving as a hub for gut microbiome therapy.
23
Country: France | Funding: $10.3M
SAS TargEDys develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia.
SAS TargEDys develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia.
24
Country: Netherlands | Funding: €250K
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
25
Country: USA | Funding: $8.4M
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing.
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing.
26
Country: Canada | Funding: $963.5K
Microbiome Insights is a global leader providing end-to-end services for microbiome DNA sequencing and state-of-the-art bioinformatics.
Microbiome Insights is a global leader providing end-to-end services for microbiome DNA sequencing and state-of-the-art bioinformatics.
27
Country: India | Funding: ₹23M
Leucine Rich Bio is India's first and only Microbiome focussed, Genomics Based company. The key areas that we work is in Preventive Healthcare and Precision Medicine.
Leucine Rich Bio is India's first and only Microbiome focussed, Genomics Based company. The key areas that we work is in Preventive Healthcare and Precision Medicine.
28
Country: UK
Biomesight is an AI-driven wellness analytics platform with a primary focus on the gut microbiome as a leading indicator of wellness.
Biomesight is an AI-driven wellness analytics platform with a primary focus on the gut microbiome as a leading indicator of wellness.
